Moderna said it would begin phase 2 trials with 600 participants shortly and finalize plans for a phase 3 trial this summer.
“We are accelerating the scale-up of manufacturing and our partnership with Lonza puts us in a position to manufacture and distribute as many doses of mRNA-1273 vaccine as possible, if it turns out to be safe and effective,” a said CEO Stephane Bancel in a statement. . The company hopes to start a phase 3 trial here in early summer, which is expected to be approved for public sale in 2021, he said.
The company’s shares jumped more than 16% in pre-market trading before losing gains after opening. At the start of the session, the stock was up almost 6%.
The company said it expects to “incur significant expenses this year” related to the development and manufacture of its potential vaccine. However, he added that he expected “a close reconciliation of expenses and reimbursements for these expenses” from his attribution by the Biomedical Advanced Research and Development Authority.
Last month, BARDA, part of the Department of Health and Human Services, provided Moderna with up to $ 483 million in funding to accelerate development of the Covid-19 vaccine candidate.
The race to develop everything to fight the coronavirus is extremely competitive and investors are watching closely for signs of progress on treatments and vaccines. Moderna, along with other companies in the race, is speeding up manufacturing before approval so that doses can be quickly dispensed if their candidate proves effective against the virus and harmless to humans.
Last week, Moderna announced a 10-year partnership with Swiss drug maker Lonza to accelerate production of the experimental vaccine. Bancel told CNBC at the time that the company hoped to start making its potential vaccine “as early as July”.
“Our team is ready to start dosing as soon as we have the green light,” said Bancel on “Squawk Box”. He added that with this partnership, the company hopes to be able to make about 1 billion doses a year.
The potential vaccine, which was developed by researchers at Moderna and the National Institutes of Health, became the first candidate to enter a human phase 1 trial in March.
The vaccine candidate uses synthetic messenger RNA to inoculate against the virus. These treatments help the body to immunize against a virus and can potentially be developed and produced faster than traditional vaccines.
Covid-19 has infected more than 3.7 million people worldwide and killed at least 264,000 people, according to data compiled by Johns Hopkins University.
As the company focuses on the development of its coronavirus vaccine candidate and the virus itself is disrupting society around the world, Moderna has warned that the development of treatments for other diseases is disrupted and delayed. Treatments affected include a potential personalized cancer vaccine and others.
The company also announced several changes in management roles related to vaccine development, regulatory affairs and infectious diseases.
“We are delighted to welcome these three new executives, who bring a wealth of experience in clinical, regulatory and business development as we begin to move towards advanced development and commercialization,” Bancel said Thursday at About new hires.
The company said it has $ 1.7 billion in cash and investments and up to $ 700 million in grants and potential rewards.